Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Strategies for accurate aggregation

The actual electronic association of the serial numbers of individual unit packages to a case is done after an inspection system on the packaging line visually inspects individual packages (or they are manually scanned) upon going into the shipping case.

In theory, there are (at least) three possible ways of handling aggregation.

The first method is by using non-line-of-sight RFID tags as the data carrier at the item level. Each drug package would have a unique RFID tag attached to it. The existing case-packing operation would require very few if any changes.

After the cases are sealed and an RFID tag containing the case-level serial number is attached, the case would be run through an RFID reader where all of the unit-level serial numbers and the case-level serial number would be read at once. The serialization solution would electronically bind those numbers to one another to form the aggregation information for that case. 

Since the cases are already sealed, there is no chance of discrepancies such as a mix-up of contents between two cases. If the RFID reader doesn’t pick up all of the expected serial numbers, the case would be rejected for quality inspection and rework.

The reason this works is that RFID doesn’t require a “line-of-sight” to read.  That is, the RFID reader can read directly through the corrugated case material and pick up all of the tags in a very short time.

The benefit is that this operation would produce 100% reliable aggregation, and so inference could be relied upon as a downstream strategy.

In the past, biologics manufacturers expressed concerns that the energy from RFID might damage the proteins in their products.  Because RFID offers advantages with cold chain products, which are often biologics, and because they can be used to track when goods move in and out of temperature-controlled areas, some biologic manufacturers have performed studies to test the impact of RFID on their goods.  Reports were published in mid-2012 on tests that indicated RFID does not harm biologics.

However, few if any companies are likely to put their unit package-level serial numbers into RFID tags unless a given country or region specifically requires it (which is always a possibility). The reality is that the vast majority of drugs will be serialized using 2D DataMatrix barcodes.  Barcodes, while much cheaper than RFID tags, require “line-of-sight” to work. 

Which brings us to method number two, which is pre-aggregation inspection. Essentially, a vision system would be placed at the entry to the case packer (or bundler or cartoner). The serialization system would keep track of individual package serial numbers as they file into the case packer. So for example, for a 12-count case or bundle, it will count the next 12 bottles that stream by the vision system and associate those numbers with the case-level serial number for the case that’s being loaded.

The benefit of this type of inspection is that it requires minimal modifications to the packaging line, which lowers costs and reduces the validation burden.

The drawback, however, is that it’s prone to unreliability. If a bottle is removed or falls off the line after that vision inspection occurs, the sequence of bottles will get out of sync by one. That means incorrect aggregation information is attributed to not only that case, but also every case after it.

Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?